uniQure Reports 2025 Financial Results, Advances Huntington’s Disease Gene Therapy and Pipeline Updates

uniQure Reports 2025 Financial Results and Provides Major Pipeline Updates

Key Highlights and Investor Takeaways

Cash Position: Ended 2025 with \$622.5 million in cash, cash equivalents, and investment securities, extending operational runway into the second half of 2029.
Clinical Progress: Advanced late-stage programs in Huntington’s disease, mesial temporal lobe epilepsy, Fabry disease, and SOD1-ALS, with significant data readouts and regulatory interactions in 2025.
Regulatory Update (Huntington’s Disease): FDA advised uniQure that current Phase I/II data for AMT-130 are insufficient for marketing approval. A new, prospective, randomized, sham-controlled Phase III trial will likely be required, impacting timelines and future expenditures.
Capital Markets Activity: Raised \$404.2 million in 2025 through public offerings and pre-funded warrants, and refinanced \$50 million in debt to extend maturity to 2030 at a lower cost of capital.
Net Loss: Reported a net loss of \$199.0 million for 2025, an improvement from \$239.6 million in 2024, with diluted loss per share at \$3.46 (vs. \$4.92 in 2024).
Upcoming Data & Catalysts: Second cohort data for AMT-260 expected 1H 2026, further regulatory updates for AMT-130, and additional clinical data from the pipeline anticipated throughout 2026.

In-Depth: Recent Company and Pipeline Developments

AMT-130 for Huntington’s Disease

Clinical Data: 36-month results from pivotal Phase I/II study showed a statistically significant 75% reduction in disease progression (cUHDRS, p=0.003) and a 60% slowing in Total Functional Capacity decline (TFC, p=0.033) in high-dose patients versus external controls. Neurofilament light protein (NfL) levels also decreased by 8.2% at 36 months.
Safety: Generally well-tolerated with no new drug-related serious adverse events since December 2022. Most adverse events were related to the administration procedure.
Regulatory Pathway: FDA, after a Type A meeting in January 2026, stated current data are not sufficient for approval and strongly recommended a new prospective, randomized, double-blind, sham-controlled Phase III study. uniQure plans a follow-up Type B meeting with the FDA in Q2 2026 to discuss study design and next steps.
Potential Share Price Impact: While data were compelling, the need for an additional Phase III trial could delay commercialization and increase costs. Investor sentiment may be affected by regulatory uncertainty and extended timelines.

AMT-260 for Refractory Mesial Temporal Lobe Epilepsy (MTLE)

Clinical Progress: Initial data from the first patient showed a 92% reduction in seizure frequency over five months with no serious safety events. First dose cohort (six patients) fully enrolled; second cohort enrollment underway with updated data expected in 1H 2026.
Significance: Early efficacy and safety results are promising, but the program remains in early-stage development. Readouts in 2026 could be a catalyst if positive.

AMT-191 for Fabry Disease

Phase I/II Data: Durable, dose-dependent increases in α-Gal A enzyme activity (up to 223.7-fold above normal at the highest dose) across 11 patients. Six patients successfully withdrawn from enzyme replacement therapy (ERT); plasma lyso-Gb3 levels remained stable post-dose.
Safety: Manageable safety profile observed; however, asymptomatic Grade 3 liver enzyme elevations in two patients led to a pause in mid/high-dose cohort dosing for further evaluation. No new serious adverse events at the highest dose since September 2025.
Investor Note: Any future resolution of the dosing pause or demonstration of a clear path to Phase III could significantly impact valuation.

AMT-162 for SOD1-ALS

Current Status: Enrollment remains voluntarily paused after a dose-limiting toxicity (serious adverse event) in one patient. Data collection continues from five treated patients as the company evaluates next steps.
Investor Risk: Uncertainty remains regarding the path forward for this program, and further safety events or program discontinuation could be share price negative.

Financial Overview

Revenue: \$16.1 million in 2025 (down from \$27.1 million in 2024), primarily due to lower collaboration and contract manufacturing revenue, partially offset by higher license revenue.
R&D Expenses: \$140.7 million (down from \$143.8 million in 2024), reflecting lower personnel and facility costs after 2024 restructuring and Lexington facility divestment, offset by increased direct expenses for AMT-130 regulatory preparation.
SG&A Expenses: \$65.5 million (up from \$52.7 million), driven by higher professional fees, including \$6.5 million related to planned commercialization of AMT-130, and increased personnel costs.
Other Income/Expense: \$14.4 million other income (up from \$7.9 million, boosted by a one-time \$6 million sale of critical reagents); \$8.0 million other expense (up from \$4.6 million, mainly related to Hemgenix® supply costs).
Net Loss: \$199.0 million (\$3.46/share, basic and diluted), improved from \$239.6 million (\$4.92/share) in 2024, reflecting operating discipline and capital raise impact.
Balance Sheet: Shareholders’ equity improved to +\$198.9 million (from a deficit of \$6.8 million in 2024).

Capital Markets and Liquidity

Public Offerings: Raised \$404.2 million through ordinary share and pre-funded warrant offerings, strengthening cash reserves.
Debt Refinancing: \$50 million debt extended to October 2030 at reduced cost; \$100 million term loan tranche available upon AMT-130 regulatory milestone; \$25 million additional tranche at lender’s discretion.
Runway: Company expects current funds to cover operations into the second half of 2029, providing stability for ongoing and planned Phase III trials.

Upcoming Catalysts

Type B FDA meeting for AMT-130 Phase III trial design (Q2 2026).
Updated clinical data from AMT-260 (1H 2026).
Resolution of dosing pause and potential updates in AMT-191 Fabry disease program.
Presentations at major investor and healthcare conferences in March and April 2026.

Risks and Shareholder Considerations

Regulatory Risk: FDA’s request for a new Phase III trial for AMT-130 may delay revenue generation and increase development costs.
Clinical Risk: Ongoing and future trial outcomes, particularly safety and efficacy data, could materially affect valuation and future funding needs.
Financial Risk: While cash runway is strong, large R&D and SG&A commitments remain, especially in the event of additional late-stage trials.
Pipeline Risk: Dosing pause and adverse events in Fabry and ALS programs highlight the inherent risks in gene therapy development.

Conclusion

uniQure’s 2025 results show meaningful scientific and financial progress, but the regulatory setback for AMT-130 in Huntington’s disease is a material development. The strong cash position and capital flexibility provide a cushion for further development, but the requirement for an additional Phase III trial delays commercialization potential and could be a key share price driver in the near term. Progress in epilepsy and Fabry programs, alongside resolution of clinical holds, will be closely watched by investors.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review uniQure’s filings with the U.S. SEC and consult their own advisors before making investment decisions.